en Related Fields Related Fields مقاله کامل Full Length/Original Article <div style="text-align: justify;"><span style="font-family:Times New Roman;"><span style="font-size:11pt"><span style="line-height:normal"><b><span style="font-size:10.5pt">Background:</span></b><span style="font-size:10.5pt"> Ovarian cancer (OC) remains the leading cause of mortality among gynecological cancers, mainly because of resistance to platinum-based chemotherapy, particularly cisplatin. This study investigated the potential of </span><span style="font-size:10.5pt">quercetin</span><span style="font-size:10.5pt"> (QU)-loaded </span><span style="font-size:10.5pt">solid lipid nanoparticles (SLNs) to address cisplatin resistance in OC cells.</span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><b><span style="font-size:10.5pt">Methods:</span></b><span style="font-size:10.5pt"> The efficacy of QU-SLN was assessed in vitro on the cisplatin-resistant SK-OV-3 and cisplatin-sensitive A2780s human OC cell lines. Various assays, including cytotoxicity, cell viability, clonogenicity, flow cytometry, quantitative RT-PCR, and wound healing assays, evaluated the combined effects of QU and QU-SLN with cisplatin on cell viability, apoptosis, gene expression levels related to cisplatin resistance, and cell migration.</span></span></span><br> <span style="font-size:11pt"><span style="line-height:normal"><b><span style="font-size:10.5pt">Results:</span></b><span style="font-size:10.5pt"> Combining QU-SLN with cisplatin resulted in significantly reduced cell viability and colony formation, accompanied by increased apoptotic rates compared to each treatment alone. Moreover, there was a notable reduction in the expression level of genes associated with cisplatin resistance, particularly <i>ABCG2</i>, <i>MT-2A</i>, <i>GST-pi</i>, and <i>XIAP</i>, in the combined treatment. Wound healing assays indicated that the QU-SLN and cisplatin combination severely impaired OC cell motility compared to cisplatin monotherapy.</span></span></span><br> <b><span style="font-size:10.5pt"><span style="line-height:115%">Conclusion:</span></span></b><span style="font-size:10.5pt"><span style="line-height:115%"> QU-SLN and cisplatin combination enhances the therapeutic response in cisplatin-resistant OC cells. By reducing cell proliferation, promoting apoptosis, and downregulating drug resistance genes, QU-SLN might present a promising strategy to improve treatment outcomes for OC patients resistant to cisplatin.</span></span></span></div> Nanoparticles, Ovarian neoplasms, Quercetin 20 35 http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-5543-2&slc_lang=en&sid=1 Masoumeh Shamsi Ndi60@yahoo.com 0000-0003-2457-7245 No Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Hossien Babaahmadi-Rezaei rash@yahoo.com 0000-0001-6818-9645 No Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Azam Khedri mojtaba@yahoo.com 0000-0001-9623-1054 No Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Mahdi Hatami mahdihatami6268@gmail.com 0000-0002-7810-5780 No Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Mojtaba Rashidi ms_rashidi60@yahoo.com 0000-0003-4311-6137 Yes Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran